Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01544881 · ClinicalTrials.gov registry record · Phase 1
Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes
A Phase 1 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01544881 is a Phase 1 study that has completed, run by Mannkind Corporation. The registered enrollment target is 17 participants.
The verdict
NCT01544881, a Phase 1 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is an Open-label, randomized study in Type 1 diabetics looking at exposure and response (PK/PD) of TI using GEN2C Inhaler versus rapid acting analog.
Interventions
- DRUG Technosphere Insulin Inhalation Powder
- DRUG Rapid Acting Analog
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01544881
The ClinicalTrials.gov registry entry for NCT01544881 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Technosphere Insulin Inhalation Powder is the first listed.
NCT01544881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01544881 about?
NCT01544881 is a clinical study titled "Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes". This is an Open-label, randomized study in Type 1 diabetics looking at exposure and response (PK/PD) of TI using GEN2C Inhaler versus rapid acting analog.
What is the current status of trial NCT01544881?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2012-03. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01544881?
The interventions under investigation include: Technosphere Insulin Inhalation Powder (DRUG), Rapid Acting Analog (DRUG).
Who is sponsoring clinical trial NCT01544881?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.